Tislelizumab is an anti-tumor drug of the PD-1 inhibitor class, mainly used for the treatment of a variety of solid tumors and hematological malignancies. Its price varies due to factors such as specification, region, and medical insurance policies. The price of a single vial (100mg/10ml) is usually in the range of RMB 2,000–3,500, and the actual selling price in medical institutions or pharmacies shall prevail.
Price Influencing Factors and Usage Recommendations
Specification and Packaging
The commonly marketed specification of tislelizumab in China is 100mg/10ml per vial. It is usually administered and purchased by treatment course (e.g., intravenous infusion once every 3 weeks), and the total cost fluctuates according to the individualized treatment regimen.
Medical Insurance and Reimbursement Policies
Tislelizumab has been included in the National Medical Insurance Catalog of China, covering approved indications including non-small cell lung cancer, Hodgkin’s lymphoma, etc. The out-of-pocket cost can be significantly reduced after reimbursement.
Medical insurance policies vary by region, so it is recommended to consult local hospitals or medical insurance authorities for details.
Purchase Channels
Tislelizumab is a prescription-only medicine and must be purchased with a doctor’s prescription in formal hospitals or designated pharmacies. Purchases through unregulated channels should be strictly avoided.
Some hospitals offer charitable drug donation or patient assistance programs; eligible patients may apply for cost reduction or exemption.
Patient Support Programs
Some pharmaceutical companies and public welfare organizations provide medication assistance, such as first-cycle free medication, ongoing medication subsidies, and other support policies. Specific details can be obtained via the attending physician or hospital pharmacy department.
Important Notes
Tislelizumab is a prescription drug and must be used strictly under medical supervision. Before treatment, a qualified physician must evaluate the indications, contraindications, and formulate an individualized treatment plan.
Immune-related adverse reactions (e.g., pneumonitis, hepatitis, etc.) may occur during treatment. Regular follow-up and monitoring are required, and any abnormal symptoms should be reported promptly.
If facing heavy financial burden, patients are advised to discuss alternative regimens with their doctor or apply for medical assistance programs.
Patients are recommended to obtain drug information through formal medical institutions, and develop a rational treatment plan based on their condition and financial situation.
